Oncology
and Radiotherapy©
18(8) 2024: 001-007 • REVIEW ARTICLE

Plasma cell leukemia: Clinical manifestations and management

Yuvraj Parmar[1], Madhumati Varma[2], Vaibhav Kaushik[3], Rajnish Kumar[4], Ravindra S. Patil[5], Devanshu J. Patel[6]

[1] Chitkara Centre for Research and Development, Chitkara University, Himachal Pradesh, India
[2] Department of General Medicine, Jaipur National University, Jaipur, India
[3] Centre of Research Impact and Outcome, Chitkara University, Rajpura, Punjab, India
[4] Department of Pharmacy, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India
[5] Department of Emergency Medicine, Krishna Institute of Medical Sciences, Maharashtra, India
[6] Department of Pharmacology, Parul University, Vadodara, Gujarat, India

ABSTRACT

The prevalent and aggressive plasma cell dyscrasia is Plasma Cell Leukaemia (PCL). The average patient survival for those with PCL is assessed in months, and their prognosis is negative. PCL can manifest on its own or after a plasma cell myeloma prodrome. Clinically aggressive PCL patients frequently demonstrate severe disease stages, bone marrow failure, extramedullary disease, a presence about certain immune phenotypic markers, such as Cluster of Differentiation 20 (CD20) expression and CD56 absence. Historically, palliative care has been the mainstay of PCL therapy, with only a smallest percentage of patients experiencing a long-lasting remission. Although uncertain if current drugs both allogeneic and autologous stem cell transplantation may be impacted by medications such as bortezomib and lenalidomide, recent research indicates that using these treatments helps PCL patients' poor prognoses.

Keywords: treatment, survival, prognosis, plasma cell leukaemia, classification

Address for correspondence:

Yuvraj Parmar

Chitkara Centre for Research and Development, Chitkara University, Himachal Pradesh, India

E-mail: yuvraj.parmar.orp@chitkara.edu.in

Word count: 3898 **Tables:** 01 **Figures:** 04 **References:** 30

Received: 14 August, 2024, Manuscript No. OAR-24-145461
Editor Assigned: 17 August, 2024, Pre-QC No. OAR-24-145461(PQ)
Reviewed: 01 September, 2024, QC No. OAR-24-145461(Q)
Revised: 08 September, 2024, Manuscript No. OAR-24-145461(R)
Published: 16 September, 2024, Invoice No. J-145461

INTRODUCTION

In general, Plasma Cell Leukaemia (PCL) diagnosis also therapy continues comparable to those for Multiple Myeloma (MM), although, despite use of new medicines PCL survival is correlated with both Autologous Stem Cell Transplantation (ASCT) is still lower than MM. New drugs offered just a slight benefit, according to epidemiology research of PCL patients conducted by Surveillance Epidemiology and End Results (SEER). ASCT-treated PCL patients had survival times of 2 years-3 years that were comparable to individuals with MM at extremely high risk [1]. When aberrant plasma cells expand out of control and invade bone marrow, circulation, and other organs, they develop into blood cancers, PCL is a common and serious kind. Despite being a subtype of multiple myeloma, PCL is more aggressive and advances more quickly. Chemotherapy, stem cell transplants, and supportive care to control symptoms and side effects are frequently used in PCL treatment. However, PCL is challenging to treat and has a dismal prognosis, having a median survival of under a year. To investigate novel therapies and enhance results for PCL patients, clinical studies are currently being conducted [2].

Uncommon leukaemia that is aggressive and has plasma cell dyscrasia is known as PCL. PCL can be further broken down into secondary PCL (sPCL) and primary PCL (pPCL), with latter generally developing an advanced and late-stage Multiple Myeloma (MM). While sPCL may occasionally be mentioned in this review, main PCL will receive a most attention. PCL is rare, however, there are notable variations in reported prevalence between populations [3]. When compared to MM, PCL exhibit distinct characteristics and more aggressive clinical behaviour. These differences include distinct molecular, increased Lactate Dehydrogenase (LDH), extramedullary involvement, increased malignant mass, 2-microglobulin, more pronounced anaemias, also thrombocytopenia is phenotypic and Bone Marrow (BM) micro environmental characteristics. Additionally, many distinctions between pPCL and sPCL have been identified, suggesting that they should be assessed as separate clinical entities [4].

There are specific chromosomal abnormalities, significant extramedullary disease, higher Lactate Dehydrogenase (LDH) levels, a malignant cone that is highly proliferative, and a lack of bone infections, which set Primary PCL (pPCL) apart from Multiple Myeloma (MM) in terms of clinicopathologic aspects.

Additionally, patients with pPCL have a diagnosis of a median Overall Survival (OS) of less than a year after standard treatment is exceedingly dismal [5]. Among B-cell cancers, lymphoplasmacytic lymphoma is prevalent, Waldenström Macroglobulinemia (WM) is distinguished as an infiltration of lymphoplasmacytic cells that is clonal inside a Bone Marrow (BM) and a monoclonal IgM component in serum. This clinically active WM might come before a pre-malignant disease, which is characterized as (IgM MGUS) Immunoglobulin- monoclonal gammopathy of unknown significance. Less than 3 g/dL of monoclonal IgM, less than 10% of BM lymphoplasmacytic cells, and no symptoms of WM illness are its defining features [6].

Patients may therefore be treated as having PCL if their Plasma Cells (PCs) make up 5% or less of their Peripheral Blood (PB) white cell differential count. The fact that multi-parametric flow cytometry method may be used to characterize plasma cell clonality is another drawback of present PCL diagnosis criteria. Another malignant clonal infection population must be established since reactive plasmacytosis can be brought on by several infections, tumours, or inflammatory diseases [7]. A particularly severe form of plasma cell disease called PCL usually develops in Relapsed/Refractory (R/R) and MM patients. PCL has a worse prognosis than MM, has a more antagonistic medical progress, and is still challenging to manage. The majority of clinical research on MM does not yet contain data on PCL patients, and this under representation represents an unmet need [8]. Flow Cytometry (FC) has offered a more reliable way for valuable tools, despite the fact that current PCL diagnosis guidelines are based on morphological assessment [9]. FC allows for not only Plasma Blast (PC) identification but also PC clonality counting and phenotypic characterisation.

The FC can discriminate between aberrant normal plasma blasts/PCs and myeloma tous PCs. These emerge from lymph nodes, travel through the PB, and eventually enter of BM niche, where they can differentiate into long-living PCs and survive. The differential diagnosis of Plasma Cell Disorders (PCDs) and reactive plasmacytosis must take this into account [10]. A substantial number of abnormal plasma cells are present in bloodstream a PCL a rare of aggressive blood malignancy. That condition affects a very small percentage of people. PCL is notoriously difficult to cure, and there are no known benefits associated with having the form of cancer. However, there may be certain therapy choices and approaches that help improve results for people afflicted with that condition [11]. That frequent and deadly kind of blood cancer called PCL develops from aberrant bone marrow plasma cells. Given that PCL is a difficult condition to manage and has a bad prognosis, its main benefits are not fully understood. It is essential to remember that PCL is a complicated illness with a range of clinical manifestations and therapeutic outcomes. As a result, not all PCL sufferers may benefit from the aforesaid benefits. For greatest results, early and correct diagnosis, tailored treatment programs, and continued monitoring are essential [12].

A common and aggressive form of blood cancer known as uncontrolled development of cancerous plasma cells in the bone marrow is a hallmark of PCL and circulatory system. Every disease affects a small percentage of people. Different from multiple of myeloma, diagnosis of PCL occurs during more than twenty percent of white blood cells present in blood are plasma cells [13]. Paper dedicated type of multiple myeloma known as primary Plasma Cell Leukaemia (pPCL) has not profited from recent advancements in medical therapy [14]. Patients with multiple myeloma or PCL who were receiving induction therapy with immunosuppressive medications or proteasome inhibitors and had already been given a diagnosis of the illness were used to develop the diagnostic criteria in the publication [15]. When examined morphologically on a Peripheral Blood (PB) smear, Circulating Plasma Cells (cPCs) were discovered to include Primary Plasma Cell Leukemia (pPCL) [16]. Paper discussed that Plasma Cell Disorders (PCD) were impacted by chronic inflammation and infections [17]. Most PCD and other chronic conditions result in recurrent infection was a substantial source of mortality and morbidity in the group even though it was not a diagnostic criterion. A blood plasma cell biosensor based on a Photonic Crystal Fibre (PCF) and exceptionally sensitive Surface Plasmon Resonance (SPR) was investigated [18].

Relapsed/Refractory (R/R) MM treatment and PCL, the study's objective was to analyse the early effectiveness and safety of a novel CAR T cell and anti-B-Cell Maturation Antigen (BCMA) [19]. Clinical outcomes were assessed in the research pertaining to sufferers of Leukaemia with Primary Plasma Cells (pPCL) who had undergone novel agent induction treatments and had peripheral blood smears that showed the existence of at least 5% clonal circulating plasma cells [20]. The purpose of the study was to review the diagnosis of primary Blood Cell Leukemia (PCL) in patients with circulating blood cells who otherwise met the diagnostic criteria for multiple myeloma [21]. Paper presented an instance that intends to illustrate need for doctors to be aware of relevance of looking at other related clinical symptoms of pPCL considering its combative nature and quick progression without medication [22]. The paper recommended a histopathologic examination as part of new skin lesions in leukaemia patients to be evaluated to make a diagnosis as quickly as feasible and to ensure proper disease treatment [23]. Paper recommends testing individuals for unexplained pH in heart failure while retaining ejection fraction, and haematological abnormalities because of plasma cell dyscrasia [24]. Study examined the clinical features of 117 patients receiving therapy for primary blood cell leukaemia (pPCL) in associated hospitals [25].

Study on hematopoietic cell transplantation and Immunomodulatory Drug (IMiD) therapy have benefited greatly from the contributions of PPCL patients, or those who have the disease [26]. Study examined 50 cases were recorded in the database as having pPCL to determine the effectiveness and prognostic value of novel treatments [27]. Modern drugs have altered the paper used to treat multiple myeloma and similar plasma cell dyscrasias, which has also had an impact on patient outcomes [28]. Paper described after receiving transplanting hematopoietic stem cells of autologous peripheral blood for his PCL, a 59-years-old male patient underwent receiving first induction chemotherapy [29]. The results of the investigation have been presented as a novel Sequencing method based on Targeted Methylation (TM) and Cell-Free Deoxyribonucleic Acid (cfDNA) that incorporates cancer signal origin prediction into a test known as the Multi Cancer Early Detection (MCED) [30].

LITERATURE REVIEW

Epidemiology

Larger case series of preliminary findings PCL patient's also particular characteristics about plasma cell myeloma, even their understanding of PCL is currently constrained by rarity of this condition. Patients with PCL, or plasma cell lymphoma, often present at a younger age as compared to other patients. PCL was originally thought to be involved in 2% to 4% of plasma cell myeloma cases. Despite the fact that viewer age differences might not be as obvious, PCL is not as common as previously thought, according to a current analysis of the Surveillance, Epidemiology, and End Results (SEER) database's surveillance, epidemiology, and end results information. The average age for people with pPCL was 67 years, despite the reality that about 2/3 of PCL sufferers was over 60 at the time of diagnosis. In addition, there were insignificant variations in this series between both non-patients and those with multiple myeloma can participate based on gender, age, or ethnicity. Patients with PCL often had lower performance status compared to those with plasma cell myeloma, increased monoclonal proteinuria, more severe monoclonal anaemia increased blood levels of calcium, creatinine, Lactate Dehydrogenase (LDH), and thrombocytopenia.

Diagnosis

PCL patients might display symptoms and anaemia, lytic bone lesions, renal failure, and hypercalcemia symptoms similar to blood cell myeloma are all connected with leukaemia, such as leucocytosis, anaemia, thrombocytopenia, diseases, and hepatosplenomegaly. The LDH and b-2-microglobulin levels in these cases may also be high. PCL patients are also more likely to have advanced illness when they first appear, and more extensive extramedullary involvement, which may affect Central Nervous System (CNS).

PCL pathologic results

Clonal plasma cells have morphological traits that fall within same range as those of other plasma cell dystrophies exist, such as mature oval-shaped plasma cells, a great deal of basophilic cytoplasm, a spherical, eccentrically positioned nucleus, and a prominent perinuclear hof. The nuclear chromatin is scattered, nucleoli are conspicuous, and nuclear to cytoplasmic ratio is high in immature plasma cells. But occasionally, myeloblasts and clonal plasma cells cannot be distinguished in PCL patients. As shown in figure 1, these clonal plasma cells have enhanced CD138, CD38, and CD20 expression and display one.



Fig. 1. Typical immune phenotypic alterations in plasma cell leukaemia patients

Typically, human leukocyte antigens Differentiation Region (DR), CD56, CD9, and CD117, and not expressed by PCL's malignant cells, compared to a majority of plasma cell myeloma patients. In addition to explaining why these clonal plasma cells are more likely to develop into leukaemia, it has been suggested that low or missing CD56 expression may also be to blame for PCL patients' greater rates of extramedullary involvement and reduced osteolytic capacity, as shown in figure 2.



Fig. 2. Patient with primary plasma cell leukaemia displaying CD38+

Protein electrophoresis in serum and urine reveals monoclonal immunoglobulin (M-protein) synthesis, which is analogous to plasma cell myeloma. In 33%, 20%, 3%, and 1% of PCL instances, IgG, IgA, IgD, and IgE, respectively, are detected, and are immunoglobulins that are most often generated, according to immunofixation. A little more than 10% of patients have consecratory PCL, whereas 35% of patients simply have a light-chain disease. A greater percentage of PCL patients than those with plasma cell myeloma have light chain disease upon diagnosis, as shown in figures 3 and 4.



Fig. 3. For λ-a-restricted, patient with primary plasma cell leukaemia



Fig. 4. Plasmodial cells -CD20

Variations in PCL's cytogenetics

In individuals with pPCL and sPCl, an abnormal karyotype was discovered in 70% and 100% of cases, respectively. In people with pPCL and sPCL, complex or hypodiploid karyotypes are typical, although Immunoglobulin Heavy chain (IgH) gene abnormalities are also extremely common on chromosome 14q32. More than 80% of individuals with pPCL and sPCL may have 14q32 translocations, and these cytogenetic abnormalities are frequently identified in individuals along with non-hyper diploid. Along either pPCL and sPCL cancers a rearrangement of 14q32, most often found Fluorescence in Situ Hybridization (FISH) partners are FGFR3/MMSET (Multiple Myeloma SET Domain) (4p16.3), CCND1 (11q13). Every prevalence about t (11;14) (q13; q32), notably individuals along with pPCL, suggests a significance of this rearrangement in pathogenesis of PCL. Monosomy 13 has been found in 2/3 of individuals with pPCL and sPCL, according to FISH investigation, which has shown a prevalent trait of these patients. Furthermore, inactivation of p53 is detected in 56% and 83% of cases, respectively, in both pPCL and sPCL cancers, where it is extremely frequent, as shown in figure 3. Those that have both pPCL and sPCL make up less than 1/3 also had MYC amplifications and Neuroblastoma Rat Sarcoma (N-RAS) Viral Oncogene Homolog or Kirsten Rat Sarcoma (K-RAS) Viral Oncogene Homolog point mutations, however, these patients may have a worse prognosis as a result.

Treatment

For PCL, there is no approved treatment at the moment. Due to the disease's low prevalence, table 1 shows that the bulk of the investigations were retrospective case series and single case reports.

Tab. 1. Plasma cell leukaemia patient characteristics in terms a treatment regimens, reactions, and clinical outcome

Regimen	Median OS (months)	N	RR (%)
Bortezomib-based	13	13	93
PAD	>11.5	5	101
M-80	23.8	9	76
SCT	29	23	NR
Allogeneic-SCT	40% at 3 years	53	NR
Thalidomide	3	6	1
VAD/CE	21	18	60
Thalidomide dex	NR	5	51
Lenalidomide dex	NR	13	76
Autologous-SCT	63% at 3 years	108	NR
MP	4	13	18

Note: Response Rate (RR), Overall Survival (OS)

The majority of current treatment plans are based on those created for multiple myeloma. Aggressive induction therapy is initial kind of treatment for PCL sufferers. In suitable patients, induction because of a diagnosis of Stem Cell Transplantation (SCT) is performed after chemotherapy since treatment alone has poor results. Patients who cannot undergo hematopoietic SCT are treated along with chemotherapy. Even though there is little information on how maintenance treatment affects PCL patients' outcomes, clinical trials addressing this crucial clinical problem have to be taken into consideration for all patients.

Induction therapy

In early management of individuals with newly diagnosed PCL, no one induction strategy is better. Conventional treatments such as melphalan and prednisone for plasma cell myeloma, had underwhelming outcomes inside PCL. Objective response was achieved by 17% of patients in a preliminary investigation, 12 pPCL patients were given prednisone and melphalan, and median overall survival was three months. A short cohort of eight individuals receiving melphalan and dexamethasone treatment at moderate dosages found a median overall survival of approximately two years at a 75% response rate. Traditional combination chemotherapy is linked with response rates of up to 59% and 15 months–20 months median overall survival. Examples of these drugs include high-dose cyclophosphamide etoposide, Vincristine, Adriamycin, and Dexamethasone (CVAD). In a small case series, therapy with intravenous vincristine and Adriamycin (hyperCVAD), fractionated high-dose cyclophosphamide, and dexamethasone all generated Complete Responses (CR) in three out of four patients, and the results were encouraging. The proteasome inhibitor bortezomib has lately gained widespread use in treatment of PCL. When used on individuals a high-risk myeloma patient, which is identified aside from chromosomal abnormalities, bortezomib outperforms other drugs in comparison. As previously mentioned, individuals with PCL frequently have the same chromosomal defects, indicating that bortezomib could be an effective treatment. Several retrospective investigations have validated an effectiveness of bortezomib in treatment of PCL into wake and several specific accounts of PCL patients that were treated with bortezomib.

Stem cell transplantation with high-dose treatment

Despite a lack of randomized evidence proving that high-dose medication than SCT is preferable to conventional treatment, transplant is advised as suitable for patients due to subpar outcomes from chemotherapy alone. The primary Case reports which research considered and retrospective investigations revealing some patients' long-lasting responses provide in Favor of this strategy. In an investigation of 21 individual's pPCL was brought on by VAD or vincristine, carmustine, melphalan, or cyclophosphamide, and had SCT in 30% of cases. Compared to patients proceeding with a transplant, 34-months median overall survival was recorded for these individuals. However, given retrospective nature, selection bias favouring younger patients that respond to treatment as a probable illness is at least partially responsible for reported survival advantage for transplant patients. Group for Blood and Marrow Transplantation was performed an extensive retrospective examination of the outcomes of 20,000 myeloma patients and individuals with pPCL in 272 individuals underwent autologous transplants from 1980 until 2006. It's interesting to note that compared to patients with myeloma, those with PCL had a higher chance of being complete remission at 100 days after transplant. Unfortunately, attainment after transplantation did not achieve a full remission result in an improvement in survival.

Prognosis

The overall prognosis for PCL is still dismal due to aggressiveness of illness and ongoing lack of efficient treatments. Survival is still only 50% even with autologous or allogeneic SCT frequently less than three years along standard chemotherapy, with a 7-months median survival time. Which predicted median overall survival of roughly two months, secondary PCL has a very terrible prognosis. Between 2000 and 2008, it was shown that the average longevity for 73 persons was 13.1 months, were treated patients with pPLC, according to a retrospective investigation. Low initial response and albumin levels >3 g/dl negatively impacted overall survival, according to a multivariable analysis. At the time of diagnosis, hypercalcaemic patients had poorer percentages of progression-free survival. However, gains in overall survival and development at 38.1 and 25.8 months, respectively, were connected to SCT.

Expert analysis

An aggressive type of plasma cell myeloma known as PCL is uncommon and challenging to treat. The bad results seen in PCL patients are a reflection of disorder's rarity, diversity in biological characteristics and biological presentation, and aggressiveness. To better comprehend basic features and PCL risk elements, biological, and genetic characteristics responsible for pPCL formation and, in situations of sPCL, plasma cell myeloma progression, effects of combining new therapeutic approaches with already established, prognosis about these patients, extensive collaboration will be necessary.

CONCLUSIONS

When aberrant plasma cells infiltrate bone marrow and the peripheral circulation, Multiple Myeloma (MM), a rare and serious variety, is known as PCL. Unfortunately, more pPCL and sPCL cases might occur due to better plasma cell myeloma therapies aging population. Given PCL's behaviour, treatment resistance, and dismal prognosis, management of disease can be difficult. Stem cell transplantation, immunotherapy, and chemotherapy are frequently used in conjunction to treat PCL. A multidisciplinary team of haematologists, oncologists, and carers should oversee PCL patients. Improvements in disease control these patients should result in a better understanding of genetic mechanisms that lead to Plasma Cell Lymphoma (sPCL) or contributing elements related to a change from Plasma Cell Lymphoma (pPCL), in addition to taking into account both risk factors unique to each patient and myeloma when choosing patient-tailored treatments. To further understand its effects on maintenance, both autologous and allogeneic SCT, including preferred treatment methods and therapy chronology for patients with PCL, combined efforts from several institutions also cooperation groups it required. It could be required to create collaborative disease-specific registries in order to better understand this rare condition. Along with preserving the quality of life for PCL patients, reducing treatment-related toxicities in elderly patients should lead to higher response rates.

LIMITATION

The rarity and aggressiveness of PCL offer difficulties. Clinical symptoms might include increased susceptibility to infections, anaemia, bone discomfort, high plasma cell counts, and elevated plasma cell counts. Because it resembles other illnesses, a timely diagnosis may be delayed. Management is difficult and often requires lengthy chemotherapy regimens, stem cell transplants, and targeted medicines such proteasome inhibitors. Because there are fewer large-scale clinical studies available due to the disease's rarity, treatment regimens are less well-established. The aggressiveness of PCL also adds to its poor prognosis, making it necessary for each patient to get individualized treatment.

REFERENCES

1. Graber JJ, Cobbs CS, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines on the use of stereotactic radiosurgery in the treatment of adults with metastatic brain tumors. Neurosurgery. 2019;84;168-170.
2. Noori M, Bahri A, Mohammadi K. Attention-guided version of 2D UNet for automatic brain tumor segmentation. IEEE. 2019;269-275.
3. Voglhuber T, Kessel KA, Oechsner M, Vogel MM, Gschwend JE, et al. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases. BMC Cancer. 2020;20:1-9.
4. Ekhator C, Nwankwo I, Rak E, Homayoonfar A, Fonkem E, et al. GammaTile: Comprehensive review of a novel radioactive intraoperative seed-loading device for the treatment of brain tumors. Cureus. 2022;14;29970.
5. Chukwueke UN, Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8.
6. Bhandari A, Koppen J, Agzarian M. Convolutional neural networks for brain tumour segmentation. Insights Imaging. 2020;11:1-9.
7. Chattopadhyay A, Maitra M. MRI-based brain tumor image detection using CNN based deep learning method. Neurosci Inform. 2022:100060.
8. D'hooghe MB, Gielen J, Van Remoortel A, D'haeseleer M, Peeters E. Single MRI-based volumetric assessment in clinical practice is associated with MS-related disability. J Magn Reson Imaging. 2019;49:1312-1321.
9. Rieke J, Eitel F, Weygandt M, Haynes JD, Ritter K. Visualizing convolutional networks for MRI-based diagnosis of Alzheimer's disease. Springer Int Publ. 2018; 24-31.
10. Bangalore Yogananda CG, Shah BR, Vejdani-Jahromi M, Nalawade SS, Murugesan GK. et al. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas. Neuro Oncol. 2020;22:402-411.
11. Havaei M, Davy A, Warde-Farley D, Biard A, Courville A. et al. Brain tumor segmentation with deep neural networks. Med Image Anal. 2017;35:18-31.
12. Dolz J, Leroy HA, Reyns N, Massoptier L, Vermandel M. A fast and fully automated approach to segment optic nerves on MRI and its application to radiosurgery. IEEE; 2015;1102-1105.
13. Pourreza R, Zhuge Y, Ning H, Miller R. Brain tumor segmentation in MRI scans using deeply-supervised neural networks. Springer Int. Publ. 2018;320-331.
14. Rani E, Grace Priya A, Indiranatchiyar A. Brain tumor detection using ANN classifier. Brain Tumor Detect Using ANN Classif. 2019;5.
15. Khan H, Shah PM, Shah MA, ul Islam S, Rodrigues JJ. Cascading handcrafted features and Convolutional Neural Network for IoT-enabled brain tumor segmentation. Comput Commun. 2020;153:196-207.
16. Sajid S, Hussain S, Sarwar A. Brain tumor detection and segmentation in MR images using deep learning. Arab J Sci Eng. 2019;44:9249-9261.
17. Rundo L, Militello C, Tangherloni A, Russo G, Vitabile S, et al. NeXt for neuro-radiosurgery: a fully automatic approach for necrosis extraction in brain tumor MRI using an unsupervised machine learning technique. Int J Imaging Syst Technol. 2018;28:21-37.
18. Zhang C, Shen X, Cheng H, Qian Q. Brain tumor segmentation based on hybrid clustering and morphological operations. Int J Biomed Imaging. 2019;2019:7305832.
19. Shivhare SN, Sharma S, Singh N. An efficient brain tumor detection and segmentation in MRI using parameter-free clustering. Springer Singapore. 2019;485-495.
20. Agn M, af Rosenschöld PM, Puonti O, Lundemann MJ, Mancini L. et al. A modality-adaptive method for segmenting brain tumors and organs-at-risk in radiation therapy planning. Med Image Anal. 2019;54:220-237.
21. Tripathi S, Sharan TS, Sharma S, Sharma N. Segmentation of brain tumour in MR images using modified deep learning network. IEEE;2021;1-5.
22. Agravat RR, Raval MS. A survey and analysis on automated glioma brain tumor segmentation and overall patient survival prediction. Arch Comput Method Eng. 2021;28:4117-4152.
23. Zhou Z, Sanders JW, Johnson JM, Gule-Monroe M, Chen M. et al. MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging. Radiother Oncol. 2020;153:189-196.
24. Cao Y, Vassantachart A, Jason CY, Yu C, Ruan D. et al. Automatic detection and segmentation of multiple brain metastases on magnetic resonance image using asymmetric UNet architecture. Phys Med Biol. 2021;66:015003.
25. Tarhini GM, Shbib R. Detection of brain tumor in MRI images using watershed and threshold-based segmentation. Int J Signal Process Syst. 2020;8:19-25.
26. Ivashchenko OV, Zhai Z, Stoel BC, Ruers TJ. Optimization of hepatic vasculature segmentation from contrast-enhanced MRI, exploring two 3D Unet modifications and various loss functions. SPIE; 2021;125-134.
27. Sahaai MB. Brain tumor detection using DNN algorithm. Turk J Comput Math Educ. 2021;12:3338-3345.
28. Yang T, Song J, Li L, Tang Q. Improving brain tumor segmentation on MRI based on the deep U-net and residual units. J Xray Sci Technol. 2020;28:95-110.
29. Deng W, Huang K, Chen X, Zhou Z, Shi C. et al. RGB-D based semantic SLAM framework for rescue robot. IEEE. 2020;6023-6028.
30. Ghosh S, Chaki A, Santosh KC. Improved U-Net architecture with VGG-16 for brain tumor segmentation. Phys Eng Sci Med. 2021;44:703-712.